14-aza prostaglandins for the treatment of glaucoma and ocular h

Details 14-aza prostaglandins for the treatment of glaucoma and ocular h 14-aza prostaglandins for the treatment of glaucoma and ocular h

1999-11-30

2000-12-12

Lee, Howard C.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

514532, 514567, 514573, 560 42, 560121, 562451, 562503, A61K 31215, A61K 31195, C07C 6974, C07C40500

Patent

active

06160013&

ABSTRACT:
14-Aza analogs of PGF.sub.2.alpha., PGD.sub.2, and PGE.sub.2 and methods of their use in treating glaucoma and ocular hypertension are disclosed.

REFERENCES:
patent: 4239778 (1980-12-01), Venton et al.
patent: 4952581 (1990-08-01), Bito et al.
patent: 5093329 (1992-03-01), Woodward et al.
patent: 5151444 (1992-09-01), Ueno et al.
patent: 5387608 (1995-02-01), Andrews
patent: 5422368 (1995-06-01), Stjernschantz et al.
patent: 5658897 (1997-08-01), Burk
patent: 5698733 (1997-12-01), Hellberg et al.
patent: 5773471 (1998-06-01), Oguchi et al.
patent: 5807892 (1998-09-01), Klimko et al.
patent: 5811443 (1998-09-01), DeSantis et al.
Alm, The Potential of Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology, 4(11):44-50 (1993).
Flach et al., Topical Prostaglandin E.sub.2 Effects on Normal Human Intraocular Pressure, Journal of Ocular Pharmacology, 4(1):13-18 (1988).
Giuffre, The Effects of Prostaglandin F.sub.2.alpha. the Human Eye, Graefe's Archive Ophthalmology, 222:139-141 (1985).
Ichikawa, et al., Molecular Aspects of the Structures and Functions of the Prostaglandin E Receptors, J. Lipid Mediators Cell Signaling 14:83-87 (1996).
Kerstetter et al., Prostaglandin F.sub.2.alpha. -1-Isopropylester Lowers Intraocular Pressure Without Decreasing Aqueous Humor Flow, American Journal of Ophthalmology, 105:30-34 (1988).
Nakajima et al., Effects of Prostaglandin D.sub.2 and its analogue, BW245C, on Intraocular Pressure in Humans, Graefe's Archive Ophthalmology, 229:411-413 (1991).
Thierauch et al., Prostaglandins and their Receptors: II. Receptor Structure and Signal Transduction, Journal of Hypertension, 12:1-5 (1994).
Waterbury, et al., EP.sub.3, But Not EP.sub.2, FP, or TP Prostanoid-Receptor Stimulation May Reduce Intraocular Pressure, Investigative Ophthalmology and Visual Science, 31(12):2560-2567 (1990).
Woodward et al., Intraocular Pressure Effects of Selective Prostanoid Receptor Agonists Involve Different Receptor Subtypes According to Radioligand Binding Studies, J. of Lipid Mediators, 6:545-553 (1993).
Woodward et al., Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP.sub.2 Receptor, Journal of Ocular Pharmacology and Therapeutics, 11(3):447-454 (1995).

Affiliated with

Also associated with

Rating

14-aza prostaglandins for the treatment of glaucoma and ocular h does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 14-aza prostaglandins for the treatment of glaucoma and ocular h, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 14-aza prostaglandins for the treatment of glaucoma and ocular h will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-218281